Increased PPAR-α activity has been shown to prevent the expression of SREBP-1c and lead to a decrease of patatin-like phospholipase domain=containing 3 (PNPLA-3) [49], which is closely related to the risks of hepatic steatosis [50]. Here, PNPLA3 is linked to fatty liver disease.